Literature DB >> 29024388

Potential biomarkers in patients with systemic sclerosis.

Andrea Delle Sedie1, Lucrezia Riente1, Lavinia Maggiorini2, Federico Pratesi2, Antonio Tavoni2, Paola Migliorini2, Ilaria Puxeddu2.   

Abstract

AIM: Reduced capillary density is considered the hallmark of systemic sclerosis (SSc) leads to tissue hypoxia, a condition that usually induces angiogenesis. The objective of our study is to investigate mediators regulating angiogenesis in SSc and to correlate their levels with serological and clinical parameters.
METHODS: vascular endothelial growth factor, fibroblast growth factor-2, endostatin, thrombospondin-1 and soluble vascular cell and intracellular adhesion molecules (sICAM-1 and sVCAM-1) were measured in sera of SSc and normal subjects by enzyme-linked immunosorbent assay.
RESULTS: Among the pro- and anti-angiogenic mediators, endostatin was significantly higher in SSc than in the control subjects. Out of the proteases involved in endostatin production, elastase but not cathepsin-L, was significantly increased in SSc patients. The soluble adhesion molecules sICAM-1 and sVCAM-1 were significantly increased and they occur in parallel. sICAM-1, but not sVCAM-1 positively correlates with the inflammatory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
CONCLUSIONS: Endostatin, elastase and the soluble adhesion molecules (sICAM-1 and sVCAM-1) are potentially involved in the pathogenesis of SSc. Moreover, the significant correlation observed between sICAM-1 and CRP and ESR indicates that sICAM-1 might be a useful biomarker of the inflammatory state of the disease.
© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  adhesion molecules; angiogenesis; elastase; endostatin; systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29024388     DOI: 10.1111/1756-185X.13196

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  4 in total

1.  Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model.

Authors:  Kai Li; Qian Wang; Qin Lv; Kelei Guo; Li Han; Peipei Duan; Yongzheng Deng; Hua Bian
Journal:  BMC Complement Med Ther       Date:  2022-06-22

2.  Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis.

Authors:  Chiara Bellocchi; Jun Ying; Ellen A Goldmuntz; Lynette Keyes-Elstein; John Varga; Monique E Hinchcliff; Marka A Lyons; Peter McSweeney; Daniel E Furst; Richard Nash; Leslie J Crofford; Beverly Welch; Jonathan G Goldin; Ashley Pinckney; Maureen D Mayes; Keith M Sullivan; Shervin Assassi
Journal:  Arthritis Rheumatol       Date:  2021-02-28       Impact factor: 10.995

Review 3.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Authors:  Olivier Bonhomme; Béatrice André; Fanny Gester; Dominique de Seny; Catherine Moermans; Ingrid Struman; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

4.  Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease.

Authors:  Biqing Huang; Jing Li; Jiuliang Zhao
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.